Interactions with supplements
Calcium
Magnesium
Vitamin D
Zinc
Look Up > Drugs > Chlorotrianisene
Chlorotrianisene
Pronunciation
U.S. Brand Names
Generic Available
Pharmacological Index
Use
Pregnancy Risk Factor
Contraindications
Warnings/Precautions
Adverse Reactions
Overdosage/Toxicology
Drug Interactions
Mechanism of Action
Pharmacodynamics/Kinetics
Usual Dosage
Mental Health: Effects on Mental Status
Mental Health: Effects on Psychiatric Treatment
Dental Health: Local Anesthetic/Vasoconstrictor Precautions
Dental Health: Effects on Dental Treatment
Patient Information
Nursing Implications
Dosage Forms

Pronunciation
(klor oh trye AN i seen)

U.S. Brand Names
TACE®

Generic Available

No


Pharmacological Index

Estrogen Derivative


Use

Treat inoperable prostatic cancer; management of atrophic vaginitis, female hypogonadism, vasomotor symptoms of menopause


Pregnancy Risk Factor

X


Contraindications

Thrombophlebitis, breast cancer, undiagnosed abnormal vaginal bleeding, known or suspected pregnancy


Warnings/Precautions

Estrogens have been reported to increase the risk of endometrial carcinoma; do not use estrogens during pregnancy


Adverse Reactions

>10%:

Cardiovascular: Peripheral edema

Endocrine & metabolic: Enlargement of breasts (female and male), breast tenderness

Gastrointestinal: Nausea, anorexia, bloating

1% to 10%:

Central nervous system: Headache

Endocrine & metabolic: Increased libido (female), decreased libido (male)

Gastrointestinal: Vomiting, diarrhea

<1%: Hypertension, thromboembolism, myocardial infarction, edema, depression, dizziness, anxiety, stroke, chloasma, melasma, rash, amenorrhea, alterations in frequency and flow of menses, decreased glucose tolerance, increased triglycerides and LDL, nausea, GI distress, cholestatic jaundice, intolerance to contact lenses, increased susceptibility to Candida infection, breast tumors


Overdosage/Toxicology

Serious adverse effects have not been reported following ingestion of large doses of estrogen-containing oral contraceptives; overdosage of estrogen may cause nausea; withdrawal bleeding may occur in females


Drug Interactions

Barbiturates may produce lower estrogen levels due to increased hepatic metabolism; may result in an increase in the pharmacologic and toxicologic effect of corticosteroids; hydantoins and rifamycins may cause an increase in metabolism of estrogen compounds


Mechanism of Action

Diethylstilbestrol derivative with similar estrogenic actions


Pharmacodynamics/Kinetics

Onset of therapeutic effect: Commonly occurs within 14 days of therapy

Distribution: Stored in fat tissues and slowly released

Metabolism: In the liver to a more potent estrogen compound


Usual Dosage

Adults: Oral:

Female hypogonadism: 12-25 mg cyclically for 21 days. May be followed by I.M. progesterone 100 mg or 5 days of oral progestin; next course may begin on day 5 of induced uterine bleeding.

Postpartum breast engorgement: 12 mg 4 times/day for 7 days or 50 mg every 6 hours for 6 doses; administer first dose within 8 hours after delivery

Vasomotor symptoms associated with menopause: 12-25 mg cyclically for 30 days; one or more courses may be prescribed

Prostatic cancer (inoperable/progressing): 12-25 mg/day


Mental Health: Effects on Mental Status

May cause depression or anxiety


Mental Health: Effects on Psychiatric Treatment

Barbiturates may increase the metabolism of estrogen resulting in lower levels


Dental Health: Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions


Dental Health: Effects on Dental Treatment

No effects or complications reported


Patient Information

Take as directed. May cause enlargement of breast (male/female), menstrual irregularity, increased libido (female), decreased libido (male), nausea or vomiting (small frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help), or acute headache (mild analgesic may help). Report persistent diarrhea; swelling of feet, hands, or legs; sudden severe headache; disturbance of speech or vision; warmth, swelling, or pain in calves; severe abdominal pain; rash; emotional lability; chest pain or palpitations; or signs of vaginal infection. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Do not get pregnant during or for 1 month following therapy. Consult prescriber for instruction on appropriate barrier contraceptive measures. This drug may cause severe fetal defects. Do not donate blood during or for 1 month following therapy. Consult prescriber if breast-feeding.


Nursing Implications

Patients should inform their physicians if signs or symptoms of thromboembolic or thrombotic disorders including sudden severe headache or vomiting, disturbance of vision or speech, loss of vision, numbness or weakness in an extremity, sharp or crushing chest pain, calf pain, shortness of breath, severe abdominal pain or mass, mental depression or unusual bleeding.


Dosage Forms

Capsule: 12 mg, 25 mg


Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved